Amplia Therapeutics Limited (ASX:ATX)
Australia
· Delayed Price · Currency is AUD 0.110
0.00 (0.00%)
At close: Mar 6, 2026
Amplia Therapeutics Income Statement
Financials in millions AUD. Fiscal year is April - March.
Millions AUD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Other Revenue | 5.01 | 3.78 | 4.45 | 1.19 | 1.98 | 1.53 | Upgrade
|
| Revenue | 5.01 | 3.78 | 4.45 | 1.19 | 1.98 | 1.53 | Upgrade
|
| Revenue Growth (YoY) | 46.79% | -15.02% | 274.34% | -40.02% | 29.33% | 4380.44% | Upgrade
|
| Cost of Revenue | 0.3 | 0.21 | 0.44 | 0.31 | 0.15 | 0.31 | Upgrade
|
| Gross Profit | 4.71 | 3.57 | 4.01 | 0.88 | 1.83 | 1.22 | Upgrade
|
| Selling, General & Admin | 3.16 | 2.67 | 2.6 | 2.2 | 1.64 | 1.13 | Upgrade
|
| Research & Development | 9.73 | 7.53 | 5.8 | 4.69 | 3.77 | 2.21 | Upgrade
|
| Operating Expenses | 13.03 | 10.37 | 8.58 | 7.17 | 5.47 | 3.56 | Upgrade
|
| Operating Income | -8.32 | -6.79 | -4.57 | -6.29 | -3.64 | -2.34 | Upgrade
|
| Interest Expense | -0.01 | -0.06 | -0.08 | -0.05 | -0 | - | Upgrade
|
| Interest & Investment Income | 0.4 | 0.28 | 0.15 | 0.1 | 0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -7.93 | -6.57 | -4.5 | -6.24 | -3.64 | -2.34 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 0.06 | Upgrade
|
| Pretax Income | -7.93 | -6.57 | -4.5 | -6.24 | -3.64 | -2.28 | Upgrade
|
| Net Income | -7.93 | -6.57 | -4.5 | -6.24 | -3.64 | -2.28 | Upgrade
|
| Net Income to Common | -7.93 | -6.57 | -4.5 | -6.24 | -3.64 | -2.28 | Upgrade
|
| Shares Outstanding (Basic) | 394 | 307 | 194 | 194 | 146 | 95 | Upgrade
|
| Shares Outstanding (Diluted) | 394 | 307 | 194 | 194 | 146 | 95 | Upgrade
|
| Shares Change (YoY) | 75.83% | 58.35% | 0.02% | 33.27% | 53.71% | 95.36% | Upgrade
|
| EPS (Basic) | -0.02 | -0.02 | -0.02 | -0.03 | -0.03 | -0.02 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.02 | -0.02 | -0.03 | -0.03 | -0.02 | Upgrade
|
| Free Cash Flow | -13.39 | -6.89 | -5.13 | -5.31 | -4.42 | -2.92 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.02 | -0.03 | -0.03 | -0.03 | -0.03 | Upgrade
|
| Gross Margin | 94.06% | 94.44% | 90.07% | 74.14% | 92.20% | 79.65% | Upgrade
|
| Operating Margin | -166.25% | -179.51% | -102.64% | -528.45% | -183.72% | -152.60% | Upgrade
|
| Profit Margin | -158.45% | -173.69% | -101.14% | -524.80% | -183.74% | -148.75% | Upgrade
|
| Free Cash Flow Margin | -267.38% | -182.04% | -115.20% | -446.19% | -222.68% | -190.52% | Upgrade
|
| EBITDA | -8.32 | -6.78 | -4.56 | -6.28 | -3.64 | -2.34 | Upgrade
|
| EBITDA Margin | -166.19% | -179.24% | -102.40% | - | -183.56% | -152.56% | Upgrade
|
| D&A For EBITDA | 0 | 0.01 | 0.01 | 0.01 | 0 | 0 | Upgrade
|
| EBIT | -8.32 | -6.79 | -4.57 | -6.29 | -3.64 | -2.34 | Upgrade
|
| EBIT Margin | -166.25% | -179.51% | -102.64% | - | -183.72% | -152.60% | Upgrade
|
| Revenue as Reported | 5.4 | 4.06 | 4.6 | 1.29 | 1.98 | 1.59 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.